Results 101 to 110 of about 5,953 (226)

Противовирусные лекарственные средства для лечения гепатита C [PDF]

, 2019
ГЕПАТИТ C /ЛЕК ТЕРПАРЕНТЕРАЛЬНО-ПЕРЕДАВАЕМЫЙ ГЕПАТИТ НИ-A, НИ-B /ЛЕК ТЕРПРОТИВОВИРУСНЫЕ СРЕДСТВА /ХИМЛЕКАРСТВ ХИМИЧЕСКАЯ СТАБИЛЬНОСТЬИНГИБИТОРЫ ПРОТЕАЗЫ NS3/NS4АИНГИБИТОРЫ БЕЛКА NS5AИНГИБИТОРЫ NS5B ПОЛИМЕРАЗЫДан обзор химической структуры и её связи с ...
Жерносек, А. К., Лагодич, А. С.   +1 more
core  

Nuevos fármacos antivirales de acción directa en una población atendida por una unidad de enfermedades infecciosas. Estudio descriptivo [PDF]

, 2017
La hepatitis C es una enfermedad infecciosa que afecta principalmente al hígado y está causada por un virus RNA de cadena positiva perteneciente a la familia Flaviviridae, género Hepacivirus, del que se conocen 7 genotipos, el último descrito ...
Gutiérrez Vélez, Rebeca
core  

Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection [PDF]

, 2018
Hepatitis C Virus (HCV) infection is major health problem worldwide, with 150 million infected people according to recent epidemiologic estimations.
Gragnani L, Monti M, Zignego AL
core   +1 more source

Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China

BMC Gastroenterology
Background Sofosbuvir/Velpatasvir (Epclusa, ECS) is the first pan-genotype direct-acting antiviral agent (DAA) for hepatitis C virus (HCV) infection, and Danoprevir (DNV) is the first DAA developed by a Chinese local enterprise, which is suitable for ...
Yunjing Zhou, Minfeng Liang, Yiting Li, Xing Chen, Jie Yang, Honglian Bai, Yingzi Long, Xiaohong Zhang, Chaoshuang Lin   +8 more
doaj   +1 more source

Efectividad y seguridad de daclatasvir/ sofosbuvir con o sin ribavirina en pacientes infectados por el genotipo 3 del virus de la hepatitis C: resultados en práctica clínica real [PDF]

, 2019
[Abstract] OBJECTIVE: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients.
Castro-Iglesias, Ángeles, Cid-Silva, Purificación, Delgado, Manuel, Margusino-Framiñán, Luis, Martín-Herranz, Isabel, Mena, Álvaro, Pernas, Berta, Pértega-Díaz, Sonia, Rodríguez-Osorio, Iria   +8 more
core   +1 more source

Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis [PDF]

, 2020
Barclay, Stephen T., Boyle, Alison, Datta, Shouren, Heydtmann, Mathis, Marra, Fiona, Peters, Erica, Priest, Matthew, Ritchie, Trina   +7 more
core   +3 more sources

STABILITY-INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR IN BULK AND TABLET DOSAGE FORMS [PDF]

, 2020
Objective: The present study was aimed to develop a novel, simple, rapid accurate and precise, stability-indicating reversed-phase high-performance liquid chromatography method for the simultaneous estimation of sofosbuvir, velpatasvir, and voxilaprevir ...
D, GOWRI SANKAR, PADMINI M, VENKATA
core   +1 more source

Sofosbuvir-Velpatasvir for Chronic Hepatitis C Virus-Infected Children and Young Adults: Efficacy and Safety

, 2023
Attique Abou Bakr, Md Shahid Sarwar, Naeem Aslam, Mamoona Ghias, Imran Mehfooz   +4 more
openalex   +2 more sources

Response Surface Optimization for Simultanous Estimation of Sofosbuvir and Velpatasvir in Human Plasma Sample [PDF]

, 2021
Rama Tulasi Jampana, Avula Prameela Rani, Panikumar Durga Anumolu   +2 more
openalex   +1 more source

Direct-Acting Antiviral Agents in Prevention of Maternal–Fetal Transmission of Hepatitis C Virus in Pregnancy

Pathogens
Prior to the Food and Drug Administration approval of ledipaspavir/sofosbuvir (Harvoni®) in 2014, the treatment of hepatitis C was interferon plus or minus ribavirin.
Christopher Hartley, Trung Van, Wikrom Karnsakul   +2 more
doaj   +1 more source